TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12953084

Group type: EXPERIMENTAL
Intervention: Oral sodium clodronate (2080 mg/day)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study: 10052021

Group type: EXPERIMENTAL
Intervention: 500 mg of vitamin C (C)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 56
Study: 7734260

Group type: EXPERIMENTAL
Intervention: Edrophonium 0.5 mg kg‐1
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Edrophonium 1.0 mg kg‐1
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.04 mg kg‐1
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Pyridostigmine 0.3 mg kg‐1
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Edrophonium 0.25 mg kg‐1 with Pyridostigmine 0.15 mg kg‐1
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Pyridostigmine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 80
Study: 1682174

Group type: EXPERIMENTAL
Intervention: distigmine bromide
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: prostaglandin F2 alpha
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: phenoxybenzamine hydrochloride
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 6174864

Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Higher-dose Human leukocyte interferon
Number of subjects: 44
Study: 29965789

Group type: EXPERIMENTAL
Intervention: Complete weightbearing restriction until week 7
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Complete weightbearing restriction until week 7 with ankle joint mobilization exercises
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Partial weightbearing from day 1 and full weightbearing from week 5
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: All groups received the same home exercise guidelines starting from week 9
Number of subjects: 75
Study: 27419258

Group type: EXPERIMENTAL
Intervention: Continuous combined oral contraceptives (COCs)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 24464122

Group type: EXPERIMENTAL
Intervention: Vibration anesthesia with dermal filler injections
Number of subjects: 41

Group type: COMPARATOR
Intervention: Dermal filler injections alone (Control)
Number of subjects: 41
Study: 22580252

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 4688
Study: 20031468

Group type: EXPERIMENTAL
Intervention: Semi-intensive multidisciplinary outpatient program (36 sessions, each lasting 2 hours)
Number of subjects: 262
Study: 17589893

Group type: EXPERIMENTAL
Intervention: Octreotide (0.5 mg s.c. every 8 h for 6 weeks, followed by octreotide LAR 20 mg i.m. at week 4-8, and octreotide LAR 30 mg i.m. every 4 weeks thereafter)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 16243985

Group type: EXPERIMENTAL
Intervention: FSNB with bupivacaine (0.125%) and clonidine (2 microg/kg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: IA with bupivacaine (0.25%) and clonidine (1 microg/kg) and morphine (5 mg)
Number of subjects: 36
Study: 12175403

Group type: EXPERIMENTAL
Intervention: Continuous leuprorelin or goserelin (both LHRH analogues), cyproterone acetate (a steroidal antiandrogen)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Close clinical monitoring
Number of subjects: 82
Study: 9657539

Group type: EXPERIMENTAL
Intervention: Fosinopril (20 mg o.d.)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Atenolol (50 mg o.d.)
Number of subjects: 50
Study: 8075734

Group type: EXPERIMENTAL
Intervention: Vaccine information pamphlets
Number of subjects: 307
Study: 2673323

Group type: EXPERIMENTAL
Intervention: Natamycin with vacuum cleaning
Number of subjects: 4

Group type: COMPARATOR
Intervention: Matched placebo spray with vacuum cleaning
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Natamycin without vacuum cleaning
Number of subjects: 4

Group type: COMPARATOR
Intervention: Matched placebo spray without vacuum cleaning
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: All groups (including both interventions)
Number of subjects: 4
Study: 4619836

Group type: EXPERIMENTAL
Intervention: Diazepam in addition to standard treatment
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 200
Study: 30753861

Group type: EXPERIMENTAL
Intervention: Multicomponent school-based educational intervention
Number of subjects: 1950

Group type: EXPERIMENTAL
Intervention: Multicomponent school-based educational intervention with free school fruit
Number of subjects: 1950

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1950
Study: 27231835

Group type: EXPERIMENTAL
Intervention: Nicardipine (n=32)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Normal saline (control group, n=32)
Number of subjects: 64
Study: 25138736

Group type: EXPERIMENTAL
Intervention: H. persicum hydroalcoholic fruit extract (300 mg/day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 24349890

Group type: EXPERIMENTAL
Intervention: School-based EDO prevention curriculum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 21719012

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural analgesia (CSEA)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Low-dose epidural analgesia (LEA)
Number of subjects: 144
Study: 18638047

Group type: EXPERIMENTAL
Intervention: Restrictive, lipid-lowering diet
Number of subjects: 50
Study: 16847150

Group type: EXPERIMENTAL
Intervention: Early intensive simvastatin therapy
Number of subjects: 3813

Group type: COMPARATOR
Intervention: Delayed conservative simvastatin strategy
Number of subjects: 3813

Group type: EXPERIMENTAL
Intervention: hsCRP >3 mg/L
Number of subjects: 3813

Group type: EXPERIMENTAL
Intervention: hsCRP 1 to 3 mg/L
Number of subjects: 3813
Study: 12878372

Group type: EXPERIMENTAL
Intervention: Eprosartan (600 mg/d for 1 week)
Number of subjects: 29
Study: 10689518

Group type: EXPERIMENTAL
Intervention: Consta Vac
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Solcotrans
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Haem‐o‐Trans
Number of subjects: 30
Study: 9499493

Group type: EXPERIMENTAL
Intervention: Intracoronary dipyridamole (0.5 mg/kg body weight)
Number of subjects: 1094

Group type: COMPARATOR
Intervention: Conventional pretreatment (heparin 15,000 I.E. and aspirin 500 mg i.v.)
Number of subjects: 1094

Group type: EXPERIMENTAL
Intervention: Intracoronary dipyridamole
Number of subjects: 1094
Study: 7704933

Group type: EXPERIMENTAL
Intervention: Interleukin-1 receptor antagonist (IL-1ra)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 3315283

Group type: EXPERIMENTAL
Intervention: Intramuscular methotrexate
Number of subjects: 127

Group type: COMPARATOR
Intervention: Oral methotrexate
Number of subjects: 127
Study: 31491796

Group type: EXPERIMENTAL
Intervention: Aminocaproic acid (2,000 mg per dose, three doses: 2 hours before surgery, 6 and 12 hours after surgery)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Tranexamic acid (1,300 mg per dose, three doses: 2 hours before surgery, 6 and 12 hours after surgery)
Number of subjects: 92
Study: 31585740

Group type: EXPERIMENTAL
Intervention: Oleuropein-enriched chocolate (40 g)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control chocolate spread (40 g)
Number of subjects: 45
Study: 29402577

Group type: EXPERIMENTAL
Intervention: Electrical stimulation (GES)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham group (GS)
Number of subjects: 30
Study: 28455172

Group type: EXPERIMENTAL
Intervention: One IPV dose at 14 weeks (SP‐1, GSK‐1, BBio‐1)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Two IPV doses at 14 and 36 weeks (SP‐2, GSK‐2, BBio‐2)
Number of subjects: 900

Group type: COMPARATOR
Intervention: One IPV dose
Number of subjects: 900

Group type: COMPARATOR
Intervention: Two IPV doses
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: All vaccines
Number of subjects: 900
Study: 25336665

Group type: EXPERIMENTAL
Intervention: Catheter Dallas lesion group (CPVI, posterior box lesion, and anterior linear ablation)
Number of subjects: 100

Group type: COMPARATOR
Intervention: CPVI group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Catheter Dallas lesion group
Number of subjects: 100
Study: 23183529

Group type: COMPARATOR
Intervention: PR48 (peginterferon-ribavirin for 44 weeks)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: BOC/RGT (boceprevir plus peginterferon-ribavirin using response guided therapy)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: BOC/PR48 (boceprevir plus peginterferon-ribavirin for 44 weeks)
Number of subjects: 178
Study: 21803011

Group type: EXPERIMENTAL
Intervention: Dronabinol 2.5 mg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Dronabinol 5.0 mg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Dronabinol
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 19398460

Group type: EXPERIMENTAL
Intervention: Intermittent bolus administration of meropenem (1 g 8 hourly)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Continuous infusion of meropenem (1 g)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All dosing regimens (intermittent bolus, extended, continuous infusion)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Extended or continuous infusion of meropenem
Number of subjects: 10
Study: 16688496

Group type: EXPERIMENTAL
Intervention: Quality of Well-Being Scale (QWB)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Health Utilities Index (HUI3)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: EQ-5D
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: HUI3
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All measures
Number of subjects: 60
Study: 15496218

Group type: EXPERIMENTAL
Intervention: Donepezil HCl 5 mg (oral) once daily from days 6 to 29
Number of subjects: 35
Study: 11669506

Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional AChE inhibitors (rivastigmine and donepezil)
Number of subjects: 0
Study: 9282800

Group type: EXPERIMENTAL
Intervention: Hepatic arterial branches supplying HCC
Number of subjects: 72

Group type: COMPARATOR
Intervention: Hepatic arterial branches not supplying HCC
Number of subjects: 72
Study: 7685428

Group type: EXPERIMENTAL
Intervention: Casodex 50 mg daily for 24 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Casodex
Number of subjects: 30
Study: 3543239

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (500 mg/m2 day 1), imidazole carboxamide (250 mg/m2 days 1 through 5), and doxorubicin (50 mg/m2 day 1)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Cyclophosphamide (500 mg/m2) and doxorubicin (50 mg/m2)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 76
Study: 31628838

Group type: EXPERIMENTAL
Intervention: High eAb-B titers
Number of subjects: 773

Group type: COMPARATOR
Intervention: Low or medium eAb-B titers
Number of subjects: 773
Study: 30179528

Group type: EXPERIMENTAL
Intervention: eTEST (HST kits with follow-up counseling)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Standard HST (HST kits with no follow-up)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control (informational letters about HIV testing locations)
Number of subjects: 65
Study: 27619827

Group type: EXPERIMENTAL
Intervention: 40 mg long‐acting octreotide once every 4 weeks for 52 weeks, in addition to standard care
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 40 mg long‐acting octreotide
Number of subjects: 62
Study: 24978156

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 22288906

Group type: EXPERIMENTAL
Intervention: Worry/Rumination Prime (WRP)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Neutral Prime (NP)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Post-priming (overall effect)
Number of subjects: 253
Study: 20175874

Group type: EXPERIMENTAL
Intervention: Retropubic tension-free vaginal tape (TVT)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Mini-sling
Number of subjects: 71
Study: 18756741

Group type: EXPERIMENTAL
Intervention: Therapy leading to a decrease in NT-pro BNP levels
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Therapy leading to a decrease in TNF-alpha levels
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Therapy leading to a decrease in IL-6 levels
Number of subjects: 61
Study: 15917043

Group type: EXPERIMENTAL
Intervention: Web-based supervisor training
Number of subjects: 176

Group type: COMPARATOR
Intervention: Non-training group (control)
Number of subjects: 176
Study: 12485787

Group type: EXPERIMENTAL
Intervention: Automatic control (slow, near-normal, near-ballistic)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Automatic control
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Near-ballistic walking (automatic control)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Hand-controlled walking
Number of subjects: 6
Study: 10796063

Group type: EXPERIMENTAL
Intervention: 300 mg enteric-coated aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular aspirin
Number of subjects: 0
Study: 8729092

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of n-3 polyunsaturated fatty acids (PUFA) from fish oils
Number of subjects: 250000

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (PUFA) ingestion
Number of subjects: 250000
Study: 8232855

Group type: EXPERIMENTAL
Intervention: Faces (6 sec inspection)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Faces (20 sec inspection)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Faces (left/right inversion of stimuli)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Vases (6 sec and 20 sec inspection)
Number of subjects: 33
Study: 3956107

Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (AVP) at 0.1 m‐unit min‐1 kg‐1
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (AVP) during tilting to 50 degrees
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low dose AVP (0.0125 m‐unit min‐1 kg‐1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High dose AVP (0.3 m‐unit min‐1 kg‐1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 5% D‐glucose
Number of subjects: 10
Study: 30171161

Group type: EXPERIMENTAL
Intervention: 10 mg [14C]finerenone (single oral administration)
Number of subjects: 4
Study: 29871045

Group type: EXPERIMENTAL
Intervention: Sternocleidomastoid muscle flaps group
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study: 24248184

Group type: EXPERIMENTAL
Intervention: 25 μg (1000 IU) vitamin D3
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: 10 μg (400 IU) vitamin D3
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study: 22890226

Group type: EXPERIMENTAL
Intervention: etafilcon A
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: narafilcon A
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: senofilcon A
Number of subjects: 120
Study: 21090563

Group type: EXPERIMENTAL
Intervention: Ipilimumab (10 mg/kg every 3 weeks for four doses)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Prophylactic oral budesonide (9 mg/d with gradual taper through week 16)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Ipilimumab
Number of subjects: 115
Study: 18675750

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nerve stimulation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 16291162

Group type: EXPERIMENTAL
Intervention: Alimemazine (0.25 mg/kg 3 times a day, maximum 2.5 mg per dose)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 12891222

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (300 mL)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (no grapefruit juice)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 6'7'-dihydroxybergamottin (in vitro)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Bergamottin (in vitro)
Number of subjects: 25
Study: 10224206

Group type: EXPERIMENTAL
Intervention: d4T plus ddI (arm 3)
Number of subjects: 108

Group type: COMPARATOR
Intervention: d4T alone (arm 2)
Number of subjects: 108

Group type: COMPARATOR
Intervention: d4T monotherapy (arm 1)
Number of subjects: 108
Study: 8722345

Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (CY) administered as a 2-h infusion (60 mg/kg) for 2 days with MESNA as intermittent bolus infusion (20% of CY dose) every 6 h
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (CY) administered by continuous infusion (1500 mg/m2/day) for 4 days with MESNA administered concomitantly at an equivalent dose to CY by continuous infusion
Number of subjects: 20
Study: 1853147

Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid (CDCA) at a dose of 15 mg/kg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) at a dose of 15 mg/kg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of CDCA and UDCA (7.5 + 7.5 mg/kg/day)
Number of subjects: 12
Study: 6430666

Group type: EXPERIMENTAL
Intervention: 2.6 mg nitroglycerin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 6.5 mg nitroglycerin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg nitroglycerin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 20 mg nitroglycerin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 20 mg nitroglycerin (6 hours later)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30500183

Group type: EXPERIMENTAL
Intervention: Random forest algorithm for virtual screening
Number of subjects: 22434

Group type: COMPARATOR
Intervention: Multi-task neural networks
Number of subjects: 22434
Study: 28918212

Group type: EXPERIMENTAL
Intervention: Miglitol (α-glucosidase inhibitor)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control period (no miglitol)
Number of subjects: 19
Study: 27194437

Group type: EXPERIMENTAL
Intervention: UltraPro Hernia System
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Prolene Hernia System
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Lichtenstein procedure
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 309
Study: 24646172

Group type: EXPERIMENTAL
Intervention: Exercise (brisk walking 20-min/day)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Dietary recommendations only
Number of subjects: 200

Group type: COMPARATOR
Intervention: Behavioural dietary recommendations
Number of subjects: 200

Group type: COMPARATOR
Intervention: Behavioural dietary recommendations + Exercise
Number of subjects: 200
Study: 22093142

Group type: EXPERIMENTAL
Intervention: Intensive multifactorial treatment (IT) including lifestyle advice and strict regulation of metabolic parameters
Number of subjects: 183

Group type: COMPARATOR
Intervention: Routine care (RC)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Intensive multifactorial treatment (IT)
Number of subjects: 183
Study: 20556536

Group type: EXPERIMENTAL
Intervention: Telephonic disease management program
Number of subjects: 295

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 295
Study: 17534233

Group type: EXPERIMENTAL
Intervention: Prolonged intra-aortic balloon pumping (IABP) for additional seven days
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group ceased IABP
Number of subjects: 39
Study: 15656848

Group type: EXPERIMENTAL
Intervention: Relaxation breathing exercise combined with physical exercise for 30 minutes daily for six weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 35
Study: 12173197

Group type: EXPERIMENTAL
Intervention: sufentanil 50 micrograms via a lumbar epidural catheter before surgery
Number of subjects: 41
Study: 10456815

Group type: EXPERIMENTAL
Intervention: Ketamine (50, 100, and 200 ng x mL(‐1))
Number of subjects: 8

Group type: COMPARATOR
Intervention: Alfentanil (50 ng x mL(‐1))
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 8
Study: 8554633

Group type: EXPERIMENTAL
Intervention: 0.2 Hz magnetic field (1.1 mT, 5 min exposure)
Number of subjects: 36

Group type: COMPARATOR
Intervention: 0.1 Hz magnetic field (1.1 mT, 5 min exposure)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham field (control)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 0.2 Hz magnetic field in second study
Number of subjects: 36
Study: 2164559

Group type: EXPERIMENTAL
Intervention: Direct electron microscopy (EM)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Presence of parvovirus
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Diagnosis of opportunistic viral infections
Number of subjects: 1
Study: 858795

Group type: EXPERIMENTAL
Intervention: Audiovisual treatment depicting a dyadic psychotherapy situation with varying therapist age and status.
Number of subjects: 60
Study: 31131818

Group type: EXPERIMENTAL
Intervention: Hemorrhoidal arteries ligation under pudendal nerve block
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doppler guided hemorrhoidal arteries ligation under spinal anaesthesia
Number of subjects: 0
Study: 28718236

Group type: EXPERIMENTAL
Intervention: Metformin Immediate Release (MIR) 1000 mg twice daily
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Metformin Extended Release (MXR) 1000 mg twice daily
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Metformin Extended Release (MXR) 500 mg twice daily
Number of subjects: 90
Study: 25371036

Group type: EXPERIMENTAL
Intervention: Individual maximum bladder capacity (MBC)
Number of subjects: 1840

Group type: COMPARATOR
Intervention: Fixed bladder volume of 500 ml
Number of subjects: 1840
Study: 23573880

Group type: EXPERIMENTAL
Intervention: Bidirectional knotless barbed suture (0-Quill™; Angiotech Pharmaceuticals, Inc.)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard sutures with either extracorporeal or intracorporeal knots (1-Monocryl®; Ethicon Inc.)
Number of subjects: 61
Study: 21771179

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0